Significant capital is being invested in artificial intelligence for drug discovery, yet traditional drug development is notoriously slow, inefficient and risky. Enter BioPhy.
The Philly-based startup was cofounded by Dave Latshaw II, a former biochemical engineer turned Johnson & Johnson executive. As CEO of BioPhy, he aims to help pharmaceutical companies use AI to bring drugs and therapies to market faster.
“The industry as a whole is unprepared for a post-artificial intelligence world in drug discovery,” Latshaw said on the latest episode of the Founding Philly podcast.
“There’s no technology platform that comprehensively addresses this challenge,” he continued. “So that’s really what we’re after — how do you create a tech-enabled development process?”
Latshaw’s pivot to entrepreneurship was driven by his passion for solving complex problems in the pharmaceutical industry, he said.
BioPhy, which he founded in 2019 with two other Wharton MBA alumni after they connected during a bowling night, has been recognized as one of the leaders on that front.
Last year the startup raised a $4.5 million seed round and as it officially launched its AI platforms, piloting them with two of the world’s largest pharma companies, Latshaw told Technical.ly. This spring it was a winner in Fast Company’s 2024 World Changing Ideas Awards.
BioPhy specifically targets the post-discovery phase, Latshaw said, using AI to accelerate drug candidates toward market readiness via two main platforms:
- BioLogicAI is an AI-powered tool that predicts clinical trial outcomes, helping companies quickly identify the most promising drug candidates. The company says that over 2,000 clinical trials, its technology accurately predicted outcomes with an 80% success rate,
- BioPhyRx is an AI companion that provides real-time guidance for scientists and regulatory professionals, streamlining everything from compliance checks to operational workflows.
Listen to the full podcast to hear about Latshaw’s journey from engineer to entrepreneur, the challenges and successes of integrating AI into a highly regulated industry, and his vision for the future of pharmaceuticals with AI.
Before you go...
Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.
3 ways to support our work:- Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
- Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
- Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Philadelphia is finally starting to explore how to regulate AI
Experts say a new metric can more accurately measure Philadelphia's income inequality, and lead to better solutions
Philly tech thrives on collaboration, but it’s not yet a regional game
